Remove tag human-centred-design
article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. Early ADC developments centred on using cytotoxins with the highest potency together with limited linker designs. cancer agent or disease-relevant toxin.

article thumbnail

CEPI provides $30m to advance novel coronavirus vaccine

European Pharmaceutical Review

Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . Manufacturing efforts for the project will be led by the UK’s Centre for Process Innovation ( CPI ) using microbes engineered by biotechnology Ingenza Ltd. 2 is the virus that causes COVID-19.).